To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Blackstone and Alnylam close R&D funding of $2bn strategic financing collaboration
Alnylam will receive up to $150 million from Blackstone Life Sciences for the development of the company's cardiometabolic disease programs vutrisiran and ALN-AGT.
